Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2013 - 2026)

Coherus Oncology has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $881000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 15.77% year-over-year to $881000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 21.93% YoY) and the FY2025 annual result came in at $3.9 million, down 25.63% from the prior year.
• Depreciation & Amortization (CF) slipped to $881000.0 in Q1 2026 per CHRS's latest filing, from $896000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.5 million in Q3 2024 and troughed at $767000.0 in Q1 2022.
• A 5-year average of $1.0 million and a median of $966000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) surged 72.3% in 2024, then slumped 37.64% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then advanced by 1.24% to $1.1 million in 2023, then dropped by 2.82% to $1.0 million in 2024, then retreated by 13.26% to $896000.0 in 2025, then retreated by 1.67% to $881000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $881000.0, $896000.0, and $966000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.